Amgen announced Sept. 20 that an intravascular ultrasound study evaluating evolocumab (Repatha) met its primary and secondary endpoints.

The new iPhone 7 allows users to register as organ donors on its built-in health app. 

Ernest Madu, MD, chairman and CEO of the Heart Institute of the Caribbean (HIC), received the inaugural global health champion award on Sept. 15 from the University of Pennsylvania’s Center for Global Health.

Researchers from the University of Alabama at Birmingham, the University of Wisconsin and Duke University received an $8 million grant from the National Heart, Lung and Blood Institute (NHLBI) to create a bioengineered, human heart tissue patch to prevent heart failure and restore heart function.

A new type 2 diabetes medication made by Janssen Pharmaceuticals that combines doses of two diabetes medications has been approved by the FDA.

A quality improvement program at the University of North Carolina significantly improved the recognition and treatment of ST-segment elevation MI (STEMI) in patients who were hospitalized at a tertiary healthcare facility in a noncardiac service.

CMS certified the University Hospitals and Health System in Jackson, Mississippi, on Aug. 17 as a facility that has met CMS’s standards for destination therapy ventricular assist devices.

Patients with type 2 diabetes who were at high cardiovascular risk and received semaglutide had a significant 26 percent lower risk of the composite endpoint of cardiovascular death, nonfatal MI or nonfatal stroke compared with a placebo group, according to a randomized trial.